BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events

ME Staff 8-k
-
0

BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01Other Events.

On September 8, 2017, BeiGene, Ltd. (the “Company”) issued a press release announcing preliminary clinicaldata from the ongoing Phase 1/2 clinical trial of its investigational PARP inhibitor BGB-290 in patients with advanced solid tumors, presented at the European Society for Medical Oncology 2017 Congress in Madrid, Spain (“ESMO”). Thefull text of this press release is filed as Exhibit 99.1to this Current Report on Form 8-K and is incorporated herein byreference.

On September 11, 2017, the Company issued a press release announcing preliminary data from multiple disease-specific subgroups in the ongoing Phase 1a/1b trial of its investigational anti-PD-1 antibody BGB-A317 in patients with advanced solid tumors, presented at ESMO. Thefull text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein byreference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release issued on September 8, 2017

99.2

Press Release issued on September 11, 2017


BeiGene, Ltd. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Exh. 99.1 – ESMO PARP PR Exhibit 99.1                                 BeiGene,…
To view the full exhibit click here

About BEIGENE,LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.